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Poloxamer 188 is a complex polydisperse mixture of non-ionic macromolecules. Adverse non-IgE-mediated hypersensitivity reactions
occur in some individuals following intravenous injection of poloxamer 188-based pharmaceuticals, presumably via complement activation.
Here we have delineated potential causal chemical and biological interactive factors behind poloxamer 188-induced complement activation in
human serum specimens. We identified the molecular constituents inherent in poloxamer 188 preparations and studied their effect on
generation of the two complement split products, SC5b-9 and Bb. Poloxamer 188 activated complement at sub-micellar concentrations and
the results indicated the potential involvement of all three known complement activation pathways. The poloxamer-induced rise of SC5b-9 in
human sera was abolished in the presence of a recombinant truncated soluble form of complement receptor type 1, thus confirming the role of
C3/C5 convertases in the activation process. Poloxamer 188-mediated complement activation is an intrinsic property of these
macromolecules and was independent of the degree of sample polydispersity, as opposed to other non-polymeric constituents. Poloxamer
188 preparations also contained unsaturated chains of diblock copolymers capable of generating SC5b-9 in human sera; this effect was
terminated following the removal of double bonds by catalytic hydrogenation. By quasi-elastic light scattering, we established interaction
between poloxamer and lipoproteins; interestingly, poloxamer-induced rise in SC5b-9 was significantly suppressed when serum HDL and
LDL cholesterol levels were increased above normal to mimic two relevant clinical situations. This observation was consistent with
previously reported data from patients with abnormal or elevated lipid profiles where no or poor complement activation by poloxamer 188
occurred. Our findings could provide the basis of novel approaches to the prevention of poloxamer-mediated complement activation.
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E-mail address: s.m.moghimi@brighton.ac.uk (S.M. Moghimi).Poloxamer 188 (Pluronic F-68, Flocork) in its entirety is
a complex polydisperse mixture of non-ionic macromole-
cules [1]. Each molecule consists of a central polypropylene
oxide chain flanked at either end by a polyethylene oxide
segment, thus forming an ABA block copolymer structure.
This copolymer has been widely tested in numerous exper-
imental and clinical situations [2–7]. For example, intrave-
nous injection or infusion of poloxamer 188 has been shown
to be of significant benefit in the management of sickle cell
1 Third Report of the National Cholesterol Education Program Expert
Panel on Detection, evaluation, and treatment of high blood cholesterol in
adults (2002), Adults Treatment Panel III, NIH Publication No. 02-5215.
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which poloxamer accelerates thrombolysis, reduces re-oc-
clusion and ameliorates re-perfusion injury. Currently, this
polymer is being evaluated for spinal cord injury and
muscular dystrophy [8]. However, adverse non-IgE-mediat-
ed hypersensitivity reactions are known to occur in some
individuals following intravenous administration of polox-
amer 188-based pharmaceuticals. Such reactions were ini-
tially reported after the administration of perfluorochemicals
emulsified with poloxamer 188 (e.g., Fluosol-DA) [9–15].
For example, Fluosol-DA infusion into rabbits and dogs has
been associated with a transient, profound hemodynamic
collapse accompanied by leukopenia and thrombocytopenia
[9,10]. In a clinical study, up to 30% of patients receiving
Fluosol-DA as an adjunct to radiation treatment of advanced
squamous tumors of the head and neck developed hypoten-
sion and/or acute respiratory distress [13]. These adverse
responses are believed to be secondary to complement
activation by poloxamer micelles [10]. Recently, these
reactions have been classified as ‘‘complement activation-
related pseudoallergy’’ and also occur following infusion of
contrast media, various drug solubilizers, and drug carriers
[16–19], and presumably is a reflection of an individual’s
immune cell sensitivity to complement-derived mediators.
In general, the incidence of pseudoallergic responses was
recently estimated to be as high as 77% of all immune-
mediated hypersensitivity reactions [17]. This estimate of
the frequency rate of pseudoallergy would predict the
occurrence of 420,000 severe pseudoallergic reactions with
approximately 20,000 fatalities every year in the United
States only [17]. Nevertheless, in view of the above appli-
cations for poloxamer 188 and the clinical importance of the
observed complement-mediated hypersensitivity reactions,
it is imperative to examine in detail and delineate the causal
chemical and biological interactive factors behind polox-
amer-induced complement activation in human sera. Under-
standing the molecular basis of these events may provide a
platform for the design of new strategies to prevent polox-
amer-mediated complement activation.
Macromolecules of similar structure but different mo-
lecular weight are known to initiate different pharmaco-
logical as well as immune responses [20,21]. Therefore,
we have determined and assessed the molecular weight
distribution and polydispersity of poloxamer preparations
and studied their effect on generation of the two comple-
ment split products, the S-protein-bound form of the
terminal complex (SC5b-9) and Bb, in human sera by
enzyme-linked immunosorbent assay. This is a sensitive
measure of the activation of the whole complement cas-
cade that involves the formation of C3a and C5a anaphy-
latoxins [18,22]. Factor Bb, a soluble by-product of factor
B, is also a specific marker of complement activation
through the alternative pathway [18]. The role of C3/C5
convertases in poloxamer-mediated complement activation
is also examined. In addition to polydispersity, the molec-
ular make-up of poloxamer preparations consist of deriv-atives arising from the manufacturing process as well as
storage conditions [1]. These constituents, which may
show batch to batch variation, could be the underlying
basis of complement-mediated adverse reactions. Hence, in
this work, we have identified and quantified these molec-
ular constituents, which consist of a range of low molec-
ular weight volatiles, unsaturated diblock chains, and
antioxidants, and studied their effect on generation of
SC5b-9 in human sera. A low incidence of complement
activation and complement-mediated adverse events have
been reported following intravenous infusion of Fluosol-
DA in to subjects with abnormal or elevated lipid profiles
[9,10,14]. On the basis of these observations, we have also
assessed interactions between poloxamer and isolated hu-
man lipoproteins and examined whether elevation of serum
concentrations of LDL and HDL cholesterol relevant to
two clinical situations (as classified by the National Cho-
lesterol Education Program Expert Panel)1 can exert a
protective role against poloxamer-mediated complement
activation.2. Materials and methods
2.1. Materials
The non-clinical grade poloxamer 188 was a kind gift
of BASF Aktiengesellschaft (Ludwigshafen, Germany) and
was used as received unless chemically modified.
Flocork (Lot 379-15-3), the clinical grade of poloxamer
188, was a gift of CytRx Corporation (GA, USA) and was
used as received. Human HDL and LDL were purchased
from Calbiochem (San Diego, CA, USA). Recombinant
soluble complement receptor type 1 (sCR1) was provided
by Avant Immunotherapeutics Incorporation (Needham,
MA, USA).
2.2. Molecular weight determination
The molecular weight of the non-clinical grade polox-
amer 188 was determined by the method of raised gel-
permeation chromatography as described earlier [23].
Briefly, poloxamer was dissolved in dimethylformamide
(2% w/v) and filtered through a 0.2 Am polyamide
membrane prior to the chromatography. Sample solutions
were passed through two columns (30 cm in length) of
Polymer Laboratory Mixed Gel, 10.0 Am (RAPRA Tech-
nology, UK) at a flow rate of 1.0 ml/min at 80 jC. The
eluent was monitored by measuring the refractive index.
The system was calibrated with poly(ethylene glycol)
(PEG), and polyethylene oxide (PEO) standards and the
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molecular masses. Due to the limited amount of Flocork,
we were unable to independently determine its molecular
weight by gel-permeation method; we quote values pro-
vided by the supplier.
2.3. Critical micelle concentration (cmc)
The cmc of non-clinical (BASF) and the clinical prepa-
ration (Flocork) of poloxamer 188 was determined by a
standard dye solubilization method at 37 jC. Briefly, known
amounts of poloxamer 188 from a stock solution were
added to stoppered glass vials in triplicate containing 2.5
mg/ml of the water-insoluble dye Sudan IV. Samples were
sonicated for 2 min and incubated overnight at 37 jC in a
shaking water bath. Following incubation, samples were
filtered through a surfactant-free cellulose acetate 0.45 Am
filter and the absorbance of each solution was measured
spectrophotometrically at k = 515 nm.
2.4. Hydrogenation of poloxamer 188
Poloxamer 188 (2 g) was reacted with a suspension of
palladium on activated carbon (2 g, 10%) in ethyl acetate
(100 ml), stirred under a hydrogen atmosphere for a
period of 5 h at which point the reaction was complete.
The catalyst was filtered out over a pad of celite and
washed with ethyl acetate (500 ml), which was evapo-
rated in vacuo to obtain the hydrogenation product. A
control reaction was performed under identical conditions
where hydrogen was replaced by nitrogen gas. Infrared
spectra were measured directly by ATR using a Nicolet
Avalar 320 FT-IR spectrometer and compared to the
original poloxamer sample. 1H-NMR spectra were deter-
mined in deuteriochloroform, with tetramethylsilane as an
internal standard with a Bruker WM 360 spectrometer.
All melting points were determined on an Electrothermal
melting point apparatus.
2.5. Head space gas chromatography (HSGC)
A Perkin-Elmer Autosystem XL with an electron capture
detector (ECD) instrument was used. The column type was
an SGE BPX5, 10 m 0.1 mm ID, 0.1 Am film thickness.
The oven program was set at 50 jC (1 min), then 5 jC/min
to 110 jC, then 20 jC/min to 220 jC, and finally held at
220 jC for 2 min. The carrier gas used was helium at 45 psi
with an injector temperature of 200 jC and an ECD
temperature of 375 jC. Injector mode was set at split.
Poloxamer 188, the hydrogenated derivative or Flocork
(10 mg) was placed into a 2 ml gas chromatography vial to
which 480 Al of HPLC grade water was added (final volume
500 Al). An internal standard 1,2-dibromopropane (0.2 ppm)
was then introduced into the vial (10 Al of a 10 ng/Al solution
of 1,2-dibromopropane in methanol). For standard addition
analysis, a volume of the polymer solution (100 ng/Al ofeach of the target compounds in HPLC grade water) was
added. Analysis was performed using this solution at a
range of volumes of between 2.5 and 10 Al. To this, 500
Al of the derivatization solution was added [1 mg/ml O-
(2,3,4,5,6-pentafluorobenzyl)hydroxylamine hydrochloride
in HPLC grade water]. Derivatization enabled us to use
ECD as a detector to increase sensitivity by a few orders of
magnitude. In addition, derivatization circumvented matrix
interference, which can result in false low readings. The gas
chromatography vial was then closed with a PTFE-lined
septum cap and mixed thoroughly then placed into an oven
at 60 jC for 15 min. A volume for headspace dispersion
(typically 50 Al) was introduced into the gas chromatogra-
phy injection port using a pre-heated 250 Al gas tight
syringe for analysis.
2.6. Inductively coupled plasma atomic emission spectro-
metry (ICP-AES)
This technique was used to determine the concentration
of Mg2 + and Ca2 + ions in the various poloxamer samples.
Initially calibration curves were constructed with standard
solutions of Mg2 + and Ca2 + over a concentration range of
0–10 ppm and measured at emission wavelengths of
k = 279.553 and k = 393.366, respectively, using a Per-
kin-Elmer Plasma 400. Samples at a concentration of 5
mg/ml in HPLC grade water were analysed at a flow rate
of 1 ml/min.
2.7. Subjects and collection of serum specimens
Blood was drawn from healthy volunteers according to
protocols approved by the Walter Reed Army Medical
Center Human Use Committee. Blood was allowed to clot
at room temperature and serum was prepared, then stored at
 80 jC. Serum samples were thawed and kept at 4 jC
before incubation with test agents.
2.8. Assay of in vitro complement activation
To measure complement activation in vitro, we deter-
mined the poloxamer 188-induced rise of the two comple-
ment split products, SC5b-9 and Bb, using enzyme-linked
immunosorbent assay kits (Quidel Co., San Diego, CA,
USA) as described in detail elsewhere [18,19]. Briefly,
poloxamer 188 or the modified forms of the copolymer
were incubated (at different concentrations) with undiluted
human serum for 30 min at 37 jC in a shaking water bath
(in triplicate determinations), at an activator to serum
volume ratio of 1:4. Typically, 10 Al of the poloxamer stock
solutions were added to 40 Al of serum placed in Eppendorf
tubes. In some experiments, the additive effects of human
HDL, LDL and organic solvents on poloxamer 188-induced
rise of the two complement split products were measured.
Zymosan was used as a control to ensure the presence of
functional complement system in human sera. In all experi-
Table 2
HSGC-ECD determination of volatile degradation products of interest in
poloxamer 188 and Flocork samples
Test sample Measured products (Ag/g)
Formaldehyde Acetaldehyde Acetonea Propionaldehyde
Poloxamer
188
0.7 188.0 not
detected
145.6
Hydrogenated
Poloxamer
188
3.4 10.8 not
detected
5.2
Flocork 1.2 55.9 not
detected
21.7
a Estimated detection limit for acetone was 1.0–5.0 Ag/g.
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was used as control.
2.9. Size analysis of human HDL and LDL
The hydrodynamic size of human lipoproteins were
measured both in the absence and presence of Flocork (5
mg/ml final concentration) by quasi-elastic light scattering,
using a Nicomp Model 370 (Pacific Scientific, Silver
Spring, MD, USA). All measurements were done in 10
mM PBS, pH 7.4, at 24 jC as described in detail elsewhere
[19]. Size measurements (volume weighting mode) were
determined at a wavelength of 633 nm, scattering angle of
90j, dispersant viscosity of 0.90 cP and refractive index of
1.33, respectively.
2.10. Statistical analysis
Data from the in vitro complement assays are expressed
as mean of triplicate determinationsF S.D. Since various
tests (poloxamer 188 and its derivatives, contaminants,
modulators) and control groups (negative control PBS,
and positive control zymosan) were run at the same time,
we had z four groups. These were subjected to one-way
ANOVA followed by the Student–Neuman–Keuls post hoc
test, as indicated by the respective experiments. The analysis
of complement activation in 17 sera was performed by
ANOVA followed by the Bonferroni post hoc test, compar-
ing only the baseline and test samples for each serum.
Differences between groups were considered significant at
P < 0.05.3. Results
3.1. Analysis of poloxamer 188 samples
Gel-permeation chromatography has demonstrated that
the non-clinical poloxamer grade is polydisperse and isTable 1
Properties of poloxamer 188 and Flocork
Property Poloxamer 188 Flocork
Weight average MW (Da)a 7361 8566
Peak Mw (Da)a 8923 8753
Polydispersitya 1.29 1.04
Low Mw components (% of total)a 3.4% 1.1%
High Mw components (% of total)a 6.8% 1.0%
CMC at 37 jC (mg/ml) 24–32 29–38
Z-average mean micelle size 14.6F 3.1 nm 12.5F 2.2 nm
Unsaturation (mEq/g) 0.02 not detected
Mg2 + content (Ag/l)b 7.0 not detected
Ca2 + content (Ag/l)b 9.0 30.0
Melting point range 51–53 jC 51–52 jC
a Values for Flocor were taken from its certificate of analysis (CytRx
Lot 379-15-3).
b Determined from a solution containing 5.0 g/l of either poloxamer 188
or Flocork.composed of molecules that range from a molecular weight
< 4500 Da (3.4% of total) to over 13,000 Da (6.8% of total),
with a weight average molecular weight of 7361 Da (Table
1). In contrast, the clinical preparation of poloxamer 188
(Flocork) has a narrow polydispersity and weight average
molecular weight of 8566 Da (analysis data was provided by
the supplier). Flocork contained 1.1% of low ( < 4500 Da)
and 1.0% of high (>13,000 Da) molecular weight compo-
nents. The non-clinical poloxamer preparation was unsatu-
rated to the extent of 0.02 mEq/g as determined by titration
with mercuric acetate. The unsaturated molecules separated
overwhelmingly into the lower molecular weight fraction
during gel-permeation chromatography. Removal of double
bonds in the whole mixture was achieved by atmospheric
pressure hydrogenation and confirmed by spectroscopy
where IR absorption signal corresponding to double bonds
(1650 cm 1) present in the starting material and the control
was absent in the hydrogenation product. Comparison of the
1H-NMR spectra of the starting material and hydrogenation
product confirmed the catalytic hydrogenation did not lead
to any degradation in the hydrogenated product. No unsat-
urated chains were detected in Flocork. Both non-clinical
and clinical preparations of poloxamer contained organic
volatiles, particularly acetaldehyde and propionaldehyde, as
determined by HSGC-ECD (Table 2). However, the quantity
of organic volatiles was considerably lower in the hydroge-
nated preparation of poloxamer 188 and Flocork.
In aqueous solution, poloxamer 188 forms micelles and
these structures are believed to initiate complement activa-
tion. Therefore, we assessed the cmc of poloxamer 188 as
well as micellar size distribution. The micelle formation in
poloxamer 188 solutions was temperature sensitive. In
accordance with previous studies [24], we were unable to
establish a cmc for poloxamer 188 at room temperature (25
jC) by established techniques. However, at physiological
temperature, both non-clinical and clinical preparations of
poloxamer 188 formed spherical micelles with a cmc in the
range of 24–32 and 29–38 mg/ml, respectively, and are in
agreement with previous reported values [24]. The average
hydrodynamic diameter for both types of micelles was < 20
nm at 37 jC as determined by photon correlation spectros-
copy (Table 1).
Fig. 2. Effect of poloxamer on SC5b-9 and Bb formation. In (a) the effect of
poloxamer concentration on SC5b-9 formation in a representative human
serum is demonstrated. Similar patterns were observed with all other tested
t Biophysica Acta 1689 (2004) 103–113 1073.2. Complement activation by poloxamer and the role of
convertases
Complement activation was assessed by measuring the
production of SC5b-9 in human sera. The data in Fig. 1
shows the changes of SC5b-9 level in sera of 17 healthy
individuals after 30 min incubation with the non-clinical
preparation of poloxamer 188 below its cmc (5 mg/ml final
concentration) at 37 jC. These observations established
statistically significant rises of serum SC5b-9 over the
control incubation (PBS) in 13 of 17 individuals. The
complement response to poloxamer varied considerably in
the individual sera, with rises in SC5b-9 levels up to 3-fold.
The results identified four non-responders (G, H, I, N)
where poloxamer failed to initiate complement activation
although these sera contained functional complement pro-
teins, as complement activation did proceed following
challenge with zymosan resulting in generation of high
levels of SC5b-9 (data not shown).
The results in Fig. 2a demonstrate the effect of polox-
amer 188 concentration on complement activation in a
typical responder serum. A poloxamer concentration as
low as 2.5 mg/ml was found to initiate complement activa-
tion. Increasing the concentration of poloxamer increases
the production of SC5b-9 in human serum. Therefore, at
concentrations below its cmc poloxamer 188 monomers can
activate the human complement system. Attempts were also
made to determine the pathway of complement activation by
the poloxamer. By excluding Ca2 + from the assay, alterna-
tive pathway activation can be distinguished easily from the
classical and mannose-binding lectin (MBL) pathways, as
Ca2 + is essential to the operation of the later pathways [18].
S.M. Moghimi et al. / Biochimica esera; *P< 0.05 and *P < 0.01 compared to control (0 mg/ml). The addition
of EGTA/Mg2+ caused partial inhibition of Sc5b-9 formation. The
difference between poloxamer incubation (10 mg/ml) and poloxamer (10
mg/ml) in the presence of EGTA/Mg2 + was statistically significant
( P< 0.05). In (b) activation of complement via the alternative pathway is
further confirmed by an increase in serum levels of Bb from four healthy
subjects. The difference between poloxamer (5 mg/ml) and control (PBS)
was statistically significant in each subject ( P < 0.01).
Fig. 1. Effect of poloxamer 188 on SC5b-9 formation in different sera
obtained from healthy subjects. Poloxamer 188 (5 mg/ml) or a
corresponding volume of PBS, as control, was incubated with serum
samples from 17 healthy volunteers and the level of SC5b-9 was
determined. The difference between poloxamer 188 and PBS was
statistically significant for all specimens ( P < 0.001 for A, B, C, D, K, O,
P and Q; P< 0.01 for E, F and L; P < 0.05 for J) except G, H, I and N
( P>0.05).The results in Fig. 2a shows that poloxamer can still cause
the formation of the SC5b-9 complex in Ca2 +-depleted
serum, but the concentration of SC5b-9 is significantly
lower (P < 0.01) in EGTA-chelated serum. These results
provide evidence that although poloxamer-induced comple-
ment activation is predominantly via the alternative path-
way, a role for the classical and the MBL pathways cannot
be excluded. Since operation of the alternative pathway is
maintained or even accelerated by elevated Mg2 + levels, we
monitored the content of both Ca2 + and Mg2 + in poloxamer
samples by ICP-AES. The results confirmed negligible
quantities of these cations in all samples (Table 1) and
hence complement activation via the alternative pathway is
not driven by sample contamination with Mg2 +. To examine
individual variation in complement activation via the alter-
Table 3
Comparison of complement activation between poloxamer 188 and its
hydrogenated product in sera of two healthy subjects
Incubations SC5b-9 (Ag/ml)
Subject 1 Subject 2
Control (PBS) 6.1F 0.8 3.5 F 0.2
Zymosan 27.4F 2.5*** 11.3F 0.6***
Poloxamer 188 10.1F1.6* 5.1F 0.3*
Hydrogenated poloxamer 14.9F 1.6** 2.1F 0.1
All p values are compared with control (PBS) and arise from one-way
ANOVA followed by the Student–Neuman–Keuls post hoc test.
*p< 0.05.
**p< 0.01.
***p< 0.001.
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was further monitored in the sera of responders. In all tested
sera, the poloxamer-induced rise of SC5b-9 was indeed
associated with a substantial individual variation in the
extent of serum Bb rise; some examples are given in Fig.
2b. The poloxamer-induced rise of SC5b-9 in all normal
sera was totally inhibited in the presence of 10 Ag/ml of a
recombinant truncated soluble form of complement receptor
type I (sCR1), two typical examples are given in Fig. 3. This
molecule inhibits complement activation both by accelerat-
ing the decay of C3 and C5 convertases, and by acting as a
co-factor for the proteolysis of C3b and C4b by factor I
[25,26].
3.3. The role of unsaturation and sample polydispersity in
complement activation
We evaluated whether the presence of unsaturated dib-
lock copolymers is a causal factor contributing to activation
of the complement cascade. This possibility was tested in
the serum of responders using the hydrogenated poloxamer
188. In order to ensure that a contaminant was not respon-
sible for the complement activation by the hydrogenated
product, a control poloxamer 188 sample was prepared
where hydrogen was replaced by nitrogen but otherwise
under identical conditions. Two different patterns were
observed. In some sera the hydrogenated product also
caused complement activation (a representative example is
subject 1), whereas in others (as represented by subject 2)
poloxamer-induced rise of SC5b-9 was abolished by prior
poloxamer hydrogenation (Table 3). Since unsaturated mol-
ecules also separate overwhelmingly into the lower molec-
ular weight fraction during gel-permeation chromatography,Fig. 3. Inhibition of poloxamer-induced complement activation by sCR1.
Inhibition occurred in all tested sera and two representative cases are
presented. The rise of SC5b-9 relative to the respected control (PBS) was
statistically significant: *P < 0.05, **P< 0.01, and ***P< 0.001.complement activation was also assessed with the peak
fraction (a fraction devoid of unsaturated molecules as well
as high molecular weight components). Again, the results
were comparable with those of the hydrogenated product in
all serum specimens (data not shown). To further determine
the role of unsaturation as well as polydispersity in com-
plement activation, Flocork was used. This attempt dem-
onstrated statistically significant rises of serum SC5b-9 in
all responders; two representative cases are presented in
Table 4. This provides clear evidence that Flocork, al-
though exhibiting low polydispersity and no unsaturation,
can cause complement activation. Again, Flocork failed to
raise SC5b-9 levels in the serum of subject 2 (as an example
of a case that did not respond to hydrogenated poloxamer
188) and the values were comparable with the control
incubation (data not shown).
3.4. The role of residual organic solvents and antioxidants
in complement activation
Experiments were also performed to assess whether
complement activation by poloxamer samples is due to the
presence of those residual organic solvents that are detected
by GC-ECD. None of the volatile molecules (final concen-
tration 0.2 mg/ml) either separately or in combination
caused elevation of serum SC5b-9 and in all cases (four
sera that responded to both poloxamer 188 and Flocork
were tested) the values were comparable to the controlTable 4
Additive effect of HDL and LDL on Flocork-mediated complement
activation in sera of two representative healthy individuals
Treatment SC5b-9 (Ag/ml)
Subject 3 Subject 4
Control (PBS) 2.7F 0.2 4.1F 0.7
Zymosan 12.0F 1.9*** 23.9F 1.3***
Flocork 7.2F 0.8*** 8.4F 0.2***
Flocork+HDL 5.4F 0.4y/** 5.1F 0.3yyy/?
Flocork+LDL 4.8F 0.4y/** 3.3F 0.2yyy/?
All p values arise from one-way ANOVA followed by the Student–
Neuman–Keuls post hoc test, compared with control (PBS): **p< 0.01,
***p< 0.001, ?p>0.05 (not significant); compared with Flocork: yp< 0.05
and yyyP < 0.001.
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molecules also failed to potentiate complement activation
by Flocork in these sera. Other likely contaminants such as
antioxidants (e.g., butylated hydroxytoluene) did not have a
role in complement activation.
3.5. Interaction of human lipoproteins with poloxamer 188
and modulation of complement activation
We evaluated the possible interaction between human
lipoproteins and Flocork and their effects on the comple-
ment cascade. Results in Fig. 4 show quasi-elastic light-
scattering analysis of the hydrodynamic size of isolated
human lipoprotein fractions both in the absence and pres-
ence of Flocork (5 mg/ml). We were unable to detect any
particles in a 5 mg/ml solution of Flocork (low photon
counts) thus confirming the absence of any micellar struc-Fig. 4. The effect of Flocork (5 mg/ml) on hydrodynamic size
distribution of isolated human serum (a) HDL and (b) LDL. Nicomp
distribution analysis was performed in the volume-weighting mode
plotting the log of particle size against relative volume. No particles
were detected in a 5 mg/ml solution of Flocork. The composition of
HDL was 2.33 mg/ml protein, 0.61 mg/ml cholesterol and 0.20 mg/ml
triglycerides. The composition of LDL was 0.94 mg/ml protein, 1.88
mg/ml cholesterol and 0.23 mg/ml triglycerides. The above pattern was
reproducible in all other preparations tested.
Fig. 5. Effect of HDL and LDL on SC5b-9 formation in serum of a healthy
individual. The rise of SC5b-9 following HDL (HDL cholesterol added = 35
mg/dl) and LDL (LDL cholesterol added = 188 mg/dl) addition relative to
control (PBS) was statistically not significant ( P>0.05). The difference
between PBS and zymosan incubations were statistically significant,
***P< 0.001. The above pattern was reproducible with all sera tested.tures. The hydrodynamic size distribution of HDL and LDL
are in agreement with their expected size (8–11 nm for
HDL and 20–30 nm for LDL). In the presence of Flocork,
the hydrodynamic size of HDL is increased as evident from
a shift to the right in the size-distribution profile. Interest-
ingly, the addition of Flocork generates two populations of
particles from LDL that differ in size distribution. One
population is classified as small-sized entities (10–20 nm)
with the majority displaying a hydrodynamic diameter of 15
nm, and a second population with particles in the range of
30–50 nm, where the majority is in the region of 28–32
nm. These observations support an interaction between
Flocork and lipoproteins. These observations were repro-
ducible with different lipoprotein preparations.
The additive effect of lipoproteins on poloxamer-medi-
ated complement activation in the sera of two representative
responders with normal cholesterol (f 180 mg/dl) and
triglyceride (f 200 mg/dl) levels is presented in Table 4.
The addition of HDL to serum specimens increased HDL
cholesterol levels by 30%. Such increased HDL cholesterol
levels are considered beneficial and represent a target for
many therapies.1 The increased cholesterol levels following
LDL addition mimicked the levels that are encountered in
heterozygous familial hypercholesterolemia (LDL choles-
terol added = 188 mg/dl), which occurs in 1/500. The results
in Table 4 show that the elevated serum HDL and LDL
cholesterol levels can suppress Flocork-mediated SC5b-9
production. This suppression is more effective with LDL
than HDL. Furthermore, suppression of complement acti-
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in lipoprotein preparations since zymosan-mediated com-
plement activation did proceed in the presence of added
lipoproteins; a representative example is presented in Fig. 5
and similar patterns were observed with other tested sera. In
the absence of poloxamer, the elevated serum levels of HDL
and LDL cholesterol had no significant effect on SC5b-9
production (Fig. 5). 
Fig. 6. Structures of D-mannose and the terminal region of poloxamer 188.
Structural similarities correspond to positions 1, 2 and 3. Only one terminal
end of poloxamer is shown, the other is identical.4. Discussion
There has been a long debate as to whether complement
activation in human serum by poloxamer 188 arises from its
polydisperse nature (particularly by those populations with
molecular weights of z 12 kDa), the presence of other
polymeric derivatives or non-polymeric constituents
[10,20,27,28]. Therefore, in this work, we have identified
and quantified the molecular constituents inherent to polox-
amer 188 preparations and studied their effect on comple-
ment activation in human sera.
Our results with the non-clinical poloxamer grade as
well as Flocork, clearly demonstrate that poloxamer-
mediated complement activation, as demonstrated with a
dramatic rise in SC5b-9 levels in sera of healthy individ-
uals, is irrespective of the degree of copolymer polydis-
persity. Furthermore, our observations with both Flocork
and the peak poloxamer 188 fraction from gel-permeation
chromatography (a fraction devoid of molecular weight
components >10 kDa) do not support an exclusive role for
the high molecular weight components as a causative
factor in complement activation. Our attention was further
focused on other constituents. Poloxamer 188 is formed by
condensation of propylene oxide and ethylene oxide under
an inert anhydrous atmosphere at elevated temperature and
pressure in the presence of an alkaline catalyst (usually
KOH) [29]. Under such conditions, elimination of a proton
from either the propylene oxide or ethylene oxide reactants
can generate an allylic double bond. Therefore, only one
chain-end will be available to react with ethylene oxide in
the second part of the poloxamer synthesis. As a result,
chains of diblock copolymers are also formed that are allyl
ether terminated on the propylene oxide side and hydroxyl
terminated on the ethylene oxide side [30]. Indeed, this
study has demonstrated, that in addition to poloxamer
chains, allylic double bonds also play some role in
complement activation, since their removal by hydrogena-
tion can totally abolish this effect in some sera. There are
also non-polymeric constituents in poloxamer samples
[1,27,28,31]. For instance, thermal oxidation of poloxamer
can occur during manufacturing, and is dominated by the
initial formation of hydroperoxides, which form primarily
at secondary carbons on the polymer backbone. The
presence of oxygen will accelerate the reaction. The
volatile products of thermal degradation, may include
formaldehyde, acetaldehyde, acetone and propionaldehyde.These contaminants could increase C3 conversion in
normal human serum particularly through inhibition of
factor I [32]. However, our experimental work with both
non-clinical and clinical preparations of poloxamer 188
does not support a primary role for volatile contaminants
and antioxidants in the generation of SC5b-9. On the basis
of the above observations, we strongly suggest that polox-
amer-mediated complement activation in human sera is an
intrinsic property of its polymeric constituents.
Poloxamer 188-induced complement activation appears
to be a complex process, and exhibits substantial interindi-
vidual variations. Poloxamer-induced rise of serum SC5b-9
was sensitive to inhibition by EGTA, at least in part, and
serum Bb levels also increased following poloxamer addi-
tion to serum. These observations indicate the potential
involvement of all three known complement activation
pathways. Complement activation through the classical
pathway is presumably initiated by the binding of naturally
occurring antibodies to poloxamer segments or to diblock
copolymers containing the allylic double bonds. However,
considering that complement activation by poloxamer oc-
curred at sub-micellar concentration, this hypothesis hinges
on the functional viability of antibody (mainly IgM)-polox-
amer mono- and oligomeric complexes. Furthermore, calci-
um-dependent complement activation can also proceed
through direct binding of C1q or MBL to the activator.
Interestingly, there are structural similarities between the
terminal PEO segments of the poloxamer and a region of D-
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activation via the lectin pathway is also possible; a hypoth-
esis that needs to be proved in future studies. The involve-
ment of the alternative pathway in complement activation
by poloxamer 188 was demonstrated by the increased serum
Bb levels over control. This activation may represent
amplification of C3 convertase initially triggered through
the calcium-sensitive pathways, or increased ‘‘C3-tick-
over’’, whereupon the highly hydrated PEO chains of
poloxamer 188 initiates increased hydrolysis of the thioester
bond in C3 to form C3(H2O), which binds factor B and
enables the bound factor B to be cleaved by factor D thus
generating soluble alternative pathway C3 convertases. In
our system, complement activation could also proceed via
some unusual routes such as direct interaction with C3 and
C4 and a conformational change, leading to products
resembling activated C3 and C4 [16]. However, this possi-
bility is unlikely since complement activation by poloxamer
188 was totally abolished in the presence of sCR1, an
inhibitor of C3/C5 convertases. Finally, poloxamer could
inhibit factors H and I, thereby enhancing alternative path-
way activation and/or amplification. The observed individ-
ual differences in SC5b-9 and Bb responses to poloxamer
are also similar to those reported previously with the non-
ionic surfactant Cremophor EL (CrEL), the solubilizing
agent for paclitaxel [19]. These differences can be attributed
to the biological variation in the plasma levels of some 15
complement proteins and the large number of positive and
negative feedback interactions.
Earlier work in human serum demonstrated that CrEL not
only caused complement activation but also substantially
decreased the electrophoretic mobility of both HDL and
LDL [33,34]. The changes in electrophoretic mobility were
associated with a shift of HDL and LDL species to a larger
molecular size with no evidence of lipoprotein dissociation
into small fragments [34]. The data suggested that these
alterations were due to incorporation of some of the hydro-
phobic components of CrEL into lipoproteins [33]. Recent-
ly, it was suggested that the components of CrEL that did
not associate with lipoproteins could form large lipid
structures that assemble C3 convertases [19]. Thus, this
structural transformation in serum appears to account for
complement activation by CrEL. Our results with HDL and
LDL also show that Flocork can interact with lipoproteins,
and alter their size. Unlike CrEL, poloxamer molecules
caused LDL dissociation and generated a population of
small-sized particles. Furthermore, the addition of Flocork
(up to 20 mg/ml) to serum did not result in the formation of
unusual or large new structures that could act as a platform
for the assembly of C3 convertases, as assessed by both
electron microscopy and quasi-light scattering (data not
shown). Remarkably, we found that the elevation of serum
HDL and LDL cholesterol levels above normal (mimicking
the relevant clinical situations) can significantly reduce
poloxamer-mediated complement activation. This prelimi-
nary observation, however, is in line with low incidence ofpoloxamer-mediated complement activation in subjects with
abnormal or elevated lipid profiles [9,10,14]. The hypoth-
esis that the elevated lipoprotein levels could provide
protection against complement activation by poloxamer
188 is worthy of exploration at a clinical level. The
molecular basis of this interaction is not clear but may be
mediated between the PEO chains of the poloxamer and
apolipoproteins [35,36]. Indeed, poloxamer-coated polysty-
rene nanospheres become surface-enriched with apolipopro-
teins following incubation in human serum [35].
A side effect of complement activation is the generation
of anaphylatoxins C3a and C5a [17]. These molecules can
induce potent biological responses at very low concentra-
tions and are involved in inflammatory and anaphylactic
reactions. Circulating leukocytes, mast cells, macrophages,
etc., express receptors for C3a and C5a. Activation of these
cells by C3a and C5a results in the release of inflammatory
mediators such as histamine and pro-inflammatory cyto-
kines, which in turn alter vascular permeability, induce
smooth muscle contraction and cause inflammatory cell
migration [22,37]. If complement activation is a contributor
to the hypersensitivity reactions to poloxamer or Flocork,
then sCR1 might provide prevention. Previous in vitro
studies have shown sCR1 to be a potent inhibitor of
complement-mediated harmful effects in 10–40 Ag/ml con-
centration range [25,26,38]. We also demonstrated that
sCR1 can effectively inhibit poloxamer-induced comple-
ment activation at 10 Ag/ml.
In summary, for the first time we have shown that
poloxamer 188-mediated complement activation is an
intrinsic property of its macromolecular components and
is irrespective of the degree of sample polydispersity. In
addition, we hypothesised that plasma lipoproteins may
control and modulate the extent of complement activation.
In the majority of sera tested, poloxamer did cause
complement activation and if complement-derived media-
tors are contributors to hypersensitivity, then our findings
could provide the basis of novel approaches to the pre-
vention of poloxamer-mediated complement activation
either by new strategies in therapeutic copolymer design
or by biochemical means. However, the ultimate goal is to
understand the molecular mechanism of ‘‘complement
activation-related pseudoallergy’’, which operates in a
small population of individuals. Future developments in
immunogenomics and predictive gene-derived toxicoge-
nomic may eventually provide new methods for assessing
an individual’s sensitivity to polymeric therapeutics and
hence reduce the risk of immunotoxicity.Acknowledgements
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